ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy (FRNP)

0,00
0,00
(0,00%)
Geschlossen 18 Juni 5:30PM

Faron Pharmaceuticals Oy (FRNP) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
-
( - )
Gebot
-
Fragen
-
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
Handelsende
-
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
125.311 €
Ausgegebene Aktien
202.881.315
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-2,14
Gewinn pro Aktie (EPS)
-0,24
Erlöse (LTM)
-
Nettogewinn (LTM)
-27,26M

Über Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like ... Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland. Mehr anzeigen

Sektor
-
Branche
-
Website
Hauptsitz
Turku, Finland
Gegründet
2026
Faron Pharmaceuticals Oy is listed in the sector of the Londoner Börse with ticker FRNP. The last closing price for Faron Pharmaceuticals Oy was -. Over the last year, Faron Pharmaceuticals Oy shares have traded in a share price range of 0,00 € to 0,00 €.

Faron Pharmaceuticals Oy currently has 202.881.315 shares in issue. Faron Pharmaceuticals Oy has a price to earnings ratio (PE ratio) of -2.14.

FRNP Neueste Nachrichten

Keine Nachrichten vorhanden.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

FRNP - Frequently Asked Questions (FAQ)

What is the current Faron Pharmaceuticals Oy share price?
The current share price of Faron Pharmaceuticals Oy is 0,00 €
How many Faron Pharmaceuticals Oy shares are in issue?
Faron Pharmaceuticals Oy has 202.881.315 shares in issue
What is the 1 year trading range for Faron Pharmaceuticals Oy share price?
Faron Pharmaceuticals Oy has traded in the range of 0,00 € to 0,00 € during the past year
What is the PE ratio of Faron Pharmaceuticals Oy?
The price to earnings ratio of Faron Pharmaceuticals Oy is -2,14
What is the registered address of Faron Pharmaceuticals Oy?
The registered address for Faron Pharmaceuticals Oy is Joukahaisenkatu 6 B, Turku, Finland Proper, 20520
What is the Faron Pharmaceuticals Oy website address?
The website address for Faron Pharmaceuticals Oy is faron.com

FRNP Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen